目的 观察嘉兴地区非小细胞肺癌(NSCLC)中生长因子受体(EGFR)基因突变与临床特点相关性.方法 采用探针扩增阻滞突变系统(ARMS)检测102例手术后组织标本的EGFR基因突变情况.结果 102例NSCLC组织中EGFR突变率为50.98％,外显子19、21突变率为67.31％.男性和女性的突变率分别为33.33％和64.91％,吸烟与不吸烟患者的EGFR基因突变率分别为37.50％、59.68％,中高度分化和低分化患者的EGFR基因突变率分别为59.02％、39.02％,腺癌和鳞癌中的突变率分别为59.04％、6.25％,差异均有统计学意义(均P＜0.05).＞60岁患者与≤60岁患者的EGFR基因突变率分别为44.93％、63.64％,术后临床分期Ⅰ+Ⅱ和Ⅲ期的EGFR基因突变率分别为49.32％、55.17％,淋巴转移和无淋巴结转移者的突变率分别为43.90％、55.74％(均P ＞0.05).结论 EGFR基因突变与性别、吸烟、腺癌、分化程度有关.%Objective To investigate the correlation of epidermal growth factor receptor (EGFR) gene mutations and clinicopathological characteristics in patients with non-small cell lung cancer (NSCLC).Methods One hundred and two surgical specimens were collected from patients with NSCLC.The EGFR gene mutations were detected by scorpion amplification refractory mutation system (ARMS).Results The mutation rate of EGFR was 50.98％ and that of exon 19/21 was 67.31％.The mutation rates of male and female were 33.33％ and 64.91％,smokers and non-smokers were 37.50％ and 59.68％,medium to high differentiated NSCLC and poorly differentiated NSCLC were 59.02％ and 39.02％,adenocarcinoma and squamous cell carcinoma were 59.04％ and 6.25％(all P＜0.05).The mutation rates of patients aged ＞60 years and ≤60 years were 44.93％ and 63.64％,clinical stages Ⅰ + Ⅱ and clinical stages Ⅲ were 49.32％ and 55.17％,lymphatic metastasis and no lymphatic metastasis were 43.90％ and 55.74％ (all P ＞0.05).Conclusion The EGFR gene mutations are correlated with sex,smoking status,pathological type and differentiation of NSCLC patients.
展开▼
